3 YEARS OF BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH HDV-RELATED COMPENSATED CIRRHOSIS: VIROLOGICAL OUTCOMES AND SAFETY DATA FROM THE RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D)

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


3 YEARS OF BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH HDV-RELATED COMPENSATED CIRRHOSIS: VIROLOGICAL OUTCOMES AND SAFETY DATA FROM THE RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D)

	AASLD 2025 Nov 7-11 Wash DC Elisabetta Degasperi1